Najnowsze wersje próbne


EudraCT Number: 2004-000806-39 Sponsor Protocol Number: CECOG/BREAST.2.2.005 Start Date: 2005-02-10
Sponsor Name: CECOG
Full Title: Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early B...
Medical condition: Early Breast Cancer
Disease: Version SOC Term Classification Code Term Level
7.0 10006199 PT
Population Age: Adults Gender: Female
Trial protocol: HU (Completed) SK (Completed)
Trial results: (No results available)

EudraCT Number: 2004-000023-15 Sponsor Protocol Number: H7T-MC-TAAL Start Date: 2005-02-10
Sponsor Name: Eli Lilly and Company Limited
Full Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention
Medical condition: Reduction of atherothrombotic events in patients with acute coronary syndromes (ACS) that is patients with ST-segment elevation MI [STEMI], non-ST-segment elevation MI [NSTEMI], or unstable angina...
Disease: Version SOC Term Classification Code Term Level
7.0 10011085 HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Completed) AT (Completed) FI (Completed) HU (Completed) CZ (Completed) SK (Completed) DE (Completed) IT (Completed) LT (Completed) EE (Completed) LV (Completed) IS (Completed) ES (Completed) DK (Completed)
Trial results: View results
EudraCT Number: 2004-000655-41 Sponsor Protocol Number: CFTY720A2308 Start Date: 2005-02-10
Sponsor Name: Novartis Farmacéutica S.A
Full Title: A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients mainta...
Medical condition: prevention of acute rejection in maintenance renal transplant recipients
Disease: Version SOC Term Classification Code Term Level
7.0 10023439 LLT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Completed)
Trial results: View results

EudraCT Number: 2004-004727-36 Sponsor Protocol Number: NR 8230-3/2004 Start Date: 2005-02-10
Sponsor Name: Charles University, 3rd Faculty of Medicine
Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.
Medical condition: Prolonged phase of critical illness after severe multiple trauma
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: CZ (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-003820-37 Sponsor Protocol Number: IGIT-008 Start Date: 2005-02-10
Sponsor Name: Bracco Imaging Spa
Full Title: A multicentre study to evaluate the Contibution of SonoVue® and CnTI technology (Contrast Tuned Imaging) to a correct classification of Adnexal Masses as benign or malignant
Medical condition: COMPLEX ADNEXAL MASS IN PELVIS
Disease: Version SOC Term Classification Code Term Level
10029104 SOC
Population Age: Adults, Elderly Gender: Female
Trial protocol: SE (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2004-005095-17 Sponsor Protocol Number: EA041999 Start Date: 2005-02-10
Sponsor Name: Engelhard Arzneimittel GmbH & Co. KG
Full Title: Randomised, double-blind, placebo-controlled, monocentric phase III study on the efficacy and safety of Lidocaine 8 mg Sore Throat Lozenges in patients with moderate to severe acute sore throat not...
Medical condition: The study will be performed in patients suffering from acute sore throat not necessarily to be treated with antibiotics
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)
EudraCT Number: 2004-003000-37 Sponsor Protocol Number: 0653A-807 Start Date: 2005-02-09
Sponsor Name: Merck & Co., Inc.
Full Title: A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) compared to Atorvastatin 20mg in Patien...
Medical condition: Hypercholesterolemia in patients with Type II Diabetes
Disease: Version SOC Term Classification Code Term Level
7.0 10020603 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: LT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2004-002172-42 Sponsor Protocol Number: Bay 38-9456/11336 Start Date: 2005-02-09
Sponsor Name: Bayer Oy
Full Title: A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediatel...
Medical condition: Erektiohäiriö
Disease: Version SOC Term Classification Code Term Level
10061461
Population Age: Adults Gender: Male
Trial protocol: FI (Completed) SE (Completed) DE (Completed) AT (Completed) GB (Completed) IT (Completed) ES (Completed)
Trial results: View results
EudraCT Number: 2004-005103-16 Sponsor Protocol Number: ETF 5450 Start Date: 2005-02-09
Sponsor Name: Estonian Science Foundation
Full Title: Central serotonergic activity measured by citalopram challenge test and platelet monoamine oxidase activity, associations with gene polymorphism (5-HTTLPR) and impulsivity
Medical condition: Healthy volunteers
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: EE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2004-004974-94 Sponsor Protocol Number: 74460 Start Date: 2005-02-09
Sponsor Name: Santen Oy
Full Title: Efficacy and safety of tafluprost 0.0015% eye drops as adjunctive therapy with timolol 0.5% eye drops. A randomised, placebo-controlled, phase III study in patients with open-angle glaucoma or ocul...
Medical condition: Open angle glaucoma or ocular hypertension
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: EE (Completed) LV (Completed)
Trial results: View results
3